精准神经退化性疾病全球市场，2024-2028

Precision Neurodegenerative Disease Market, Global, 2024-2028

出版日期: 2024年08月26日 | 出版商:

Frost & Sullivan | 英文 75 Pages | 商品交期: 最快1-2个工作天内

价格

简介目录

将人工智慧能力、缓解疾病治疗和产业相结合将推动精准 NDD 治疗的变革性成长

全球神经退化性疾病（NDD）盛行率的上升正在推动从症状治疗转向针对独特病理机制（例如蛋白质错误折迭、发炎和突触功能障碍）的缓解疾病治疗的转变，因此需要根据独特的基因光谱客製化治疗方法。 Precision NDD 正在改变临床试验设计，导致使用数位双胞胎进行基于精确诊断的试验和自适应小规模临床试验设计。专注于精准 NDD 的公司正在采用下一代生物资讯学、体学和药物遗传学来开发机制特异性的治疗方法。神经类器官、表观基因研究平台和生物资讯解决方案等研究工具可实现资料驱动的临床和转化研究。预测 NDD 风险的新型生物和数位生物标记以及遗传变异的发现和检验是一项突破。基于人工智慧、机器学习、机器人技术和巨量资料的多组体学工具正在提高目标识别/检验的准确性，以减少临床试验失败，这是 NDD 药物研发的关键挑战。表观遗传疗法、主动免疫治疗和蛋白水解疗法等治疗方法，以及定序伴同性诊断、神经影像学和单光子发射断层扫描等精密模式，将用于精密NDD。奈米颗粒创新正在创造可以穿过血脑障壁的靶向药物输送解决方案。

涵盖了全球精准 NDD 行业的进展，包括对影响 NDD 领域创新疗法和平台采用的趋势的分析。精准 NDD 产业正在经历变革时期，整个医药价值链中精准医疗 (PH) 应用的整合，包括药物发现和开发解决方案、标靶治疗治疗、监测和患者支持解决方案。见解包括阿兹海默症和帕金森氏症的行业概况和临床实验状况、整体监管趋势、不断发展的治疗方法的未来前景、PH 对手术干预的影响、数位医疗技术製药融合等。它提供了对正在开发突破性技术、治疗方法、生物标记和诊断成像进步的创新公司的见解，这些技术、治疗方法、生物标记和诊断成像进步正在改变阿兹海默症和帕金森氏病的治疗。製药、诊断和医疗设备参与者之间的策略整合强调使用数位和医疗技术来检测、管理和监测疾病进展并提供客製化治疗，并可以填补 NDD 管理中的重要空白。这项研究服务确定了最受欢迎和新兴的经营模式经营模式，有助于填补 NDD 管理方面的空白。这使得产业参与者能够增强他们的竞争力、服务产品和地理推广。它还透过确定关键的市场驱动因素、限制因素、伙伴关係以及当前和未来的趋势来解决患者获取不足的挑战。

NDD产业概况-产业现状
开发平臺和产业概况 - AD
研发开发平臺和产业概况 - PD
AD临床试验现状
临床试验状态-PD
研发的主要挑战－测试失败率高
价值提案- 为什么精准干预至关重要
PH在神经退化性疾病的应用
推动市场成长的趋势
政府政策和监管趋势
市场准入实施通讯协定
精准医疗价值链中的经营模式与伙伴关係
经营模式
伙伴关係影响
整合活动
前景

适应症使用案例—阿兹海默症

现状与挑战
盛行率和经济负担的预测
未满足的核心需求和产业参与者的焦点
PM 应用中的新解决方案
趋势与新技术-AD
特色企业

适应症使用案例－帕金森氏症

现状与挑战
盛行率和经济负担的预测
未满足的核心需求和产业相关人员的焦点
PM 应用的新解决方案
产业趋势及新技术-PD
值得关注的公司

成长机会宇宙

用于 RA、AD 和 PD 患者的 Growth Opportunity 1-GLP-1 胰岛素製剂
成长机会2－基于神经技术的精准治疗
成长机会3 - 罕见NDD的多目标策略
成长机会4－人工智慧在神经保护治疗的整合
图表列表
免责声明

简介目录

Product Code: PFOO-52

Precision NDD Treatment is Experiencing Transformational Growth due to AI Capabilities, Disease-modifying Therapies, and Industry Convergence

The rising global prevalence of neurodegenerative diseases (NDDs) is driving the shift from symptom-to-disease-modifying therapeutics that target unique pathological mechanisms, such as protein misfolding, neuroinflammation, and synaptic dysfunction, and customizing treatment based on unique genetic profiles, disease subtypes, and distinct biomarkers. Precision NDD has changed clinical trial design, resulting in precision diagnostics-based studies and the use of digital twins for adaptive and small-sized clinical trial designs. Precision NDD-focused companies employ next-generation bioinformatics, omics, and pharmacogenetics to develop mechanism-specific therapy approaches. Precision research tools, such as neural organoids, platforms for pharmacoepigenomics studies, and bioinformatics solutions, enable data-driven clinical and translational research. The discovery and validation of novel biological and digital biomarkers, and genetic variants to predict NDD risk are breakthroughs. AI, ML, robotics, and big data-based multi-omics tools are improving the degree of precision for target identification/validation to limit clinical trial failures, a critical challenge for NDD drug R&D. Therapeutic approaches such as epigenetic therapy, active immunotherapies, protein degradation therapies, and precision modalities, such as sequencing companion diagnostics, neuroimaging, and single photon emission computed tomography, will be adopted for precision NDD. Innovations in nanoparticles are creating game-changing targeted drug delivery solutions that can cross the blood-brain barrier.

Advancements in the global precision NDD industry, including analysis relating to trends shaping the uptake of innovative therapeutics and platforms in the NDD landscape, are covered. The precision NDD industry is undergoing a transformative shift, driven by the integration of precision health (PH) applications across the pharmaceutical value chain, covering drug discovery and development solutions, targeted therapeutics, and monitoring and patient support solutions. Insights include an industry overview and clinical trial landscape of Alzheimer's disease and Parkinson's disease, prevailing regulatory trends, the future outlook of evolving therapeutic modalities, the impact of PH on surgical interventions, and digital-MedTech-Pharma convergence. Insights are provided into game-changing companies developing innovative technologies and treatment modalities, biomarkers, and imaging advancements that are transforming the management of Alzheimer's and Parkinson's diseases. Strategic integration among pharma, diagnostics, and medical device players is highlighted because the convergence of capabilities fills vital gaps in the management of NDDs by enabling the use of digital and MedTech technologies to detect, manage, and monitor disease progression and administer customized therapeutics. The research service identifies the most prevalent and emerging business models that help bridge the gaps in NDD management. This enables industry participants to enhance their competitiveness, service offerings, and geographic outreach. It also addresses the challenges of inadequate patient access by highlighting the primary market drivers, restraints, partnerships, and present and future trends.

Strategic Imperatives

Why is it Increasingly Difficult to Grow?
The Strategic Imperative 8™
The Impact of the Top 3 Strategic Imperatives on the Precision Neurodegenerative Disease (NDD) Industry
Growth Opportunities Fuel the Growth Pipeline Engine™